title: The changing epidemiology of sudden death in heart failure.
abstract: Worsening and progressive heart failure has been the most common mode of death in patients with heart failure. With the development of drugs that primarily have modulation of the renin-angiotensin and sympathetic nervous systems as their mechanism, relative importance of progressive heart failure has decreased. Sudden death has become a larger issue and the dominant mode of death in heart failure. This change requires the clinician to redirect therapy to the prevention and treatment of sudden death.
authors.affiliation: Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, 2799 West Grand Boulevard, Detroit, MI 48202, USA. sgoldst1@hfhs.org
authors.forename: Sidney
authors.initials: S
authors.lastname: Goldstein
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D006333:Heart Failure / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality*; D006334:Heart Function Tests; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents